Voronoi Announces Phase 1 Results for Targeted Anticancer Drug 'VRN10'…"Encouraging Results"
Predicted impact: Low
Phase 1 clinical trial results for a drug candidate; no revenue size or financial impact given.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.